Terms: = Skin cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207
1930 results:
1. miRSNP rs188493331: A key player in genetic control of microRNA-induced pathway activation in hypertrophic scars and keloids.
Chen M; Pan Y; Chen Z; Qi F; Gu J; Qiu Y; He A; Liu J
Skin Res Technol; 2024 May; 30(5):e13686. PubMed ID: 38682767
[TBL] [Abstract] [Full Text] [Related]
2. Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs.
Kraft T; Grützmann K; Meinhardt M; Meier F; Westphal D; Seifert M
Acta Neuropathol Commun; 2024 Apr; 12(1):67. PubMed ID: 38671536
[TBL] [Abstract] [Full Text] [Related]
3. Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment.
Zhang Y; Zheng J; Chen M; Zhao S; Ma R; Chen W; Liu J
BMC Cancer; 2024 Apr; 24(1):519. PubMed ID: 38654216
[TBL] [Abstract] [Full Text] [Related]
4. Artesunate attenuates the tumorigenesis of choroidal melanoma via inhibiting EFNA3 through Stat3/akt signaling pathway.
Yao N; Ma Q; Yi W; Zhu Y; Liu Y; Gao X; Zhang Q; Luo W
J Cancer Res Clin Oncol; 2024 Apr; 150(4):202. PubMed ID: 38630320
[TBL] [Abstract] [Full Text] [Related]
5. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
6. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-akt signaling pathway-mediated Keratin 14 degradation.
Zhou K; Wu C; Cheng W; Zhang B; Wei R; Cheng D; Li Y; Cao Y; Zhang W; Yao Z; Zhang X
Cell Death Dis; 2024 Apr; 15(4):252. PubMed ID: 38589352
[TBL] [Abstract] [Full Text] [Related]
7. Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.
Mahmood N; Arakelian A; Szyf M; Rabbani SA
Exp Mol Med; 2024 Apr; 56(4):959-974. PubMed ID: 38556549
[TBL] [Abstract] [Full Text] [Related]
8. LPCAT1 promotes melanoma cell proliferation via akt signaling.
Wang Y; Huang Y; Wang Y; Zhang W; Wang N; Bai R; Luo R; Tuo H; Zheng Y
Oncol Rep; 2024 May; 51(5):. PubMed ID: 38551165
[TBL] [Abstract] [Full Text] [Related]
9. Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression.
Lee YH; Yoon AR; Yun CO; Chung KC
J Biol Chem; 2024 Apr; 300(4):107206. PubMed ID: 38519031
[TBL] [Abstract] [Full Text] [Related]
10. [Yes-associated protein (YAP) promotes invasion and migration of cutaneous squamous cell carcinoma cells by activating the PI3K/akt pathway].
Li Z; Yang F; Jin X; Wang X; Chen T; Quan C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):244-251. PubMed ID: 38512035
[TBL] [Abstract] [Full Text] [Related]
11. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.
Muraro E; Montico B; Lum B; Colizzi F; Giurato G; Salvati A; Guerrieri R; Rizzo A; Comaro E; Canzonieri V; Anichini A; Del Vecchio M; Mortarini R; Milione M; Weisz A; Pizzichetta MA; Simpson F; Dolcetti R; Fratta E; Sigalotti L
Front Immunol; 2024; 15():1336566. PubMed ID: 38510242
[TBL] [Abstract] [Full Text] [Related]
12. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives.
Malekan M; Haass NK; Rokni GR; Gholizadeh N; Ebrahimzadeh MA; Kazeminejad A
Life Sci; 2024 May; 345():122563. PubMed ID: 38508233
[TBL] [Abstract] [Full Text] [Related]
13. Persistent β-Hexachlorocyclohexane Exposure Impacts Cellular Metabolism with a Specific Signature in Normal Human Melanocytes.
Papaccio F; Caputo S; Iorio A; De Simone P; Ottaviani M; Del Brocco A; Frascione P; Bellei B
Cells; 2024 Feb; 13(5):. PubMed ID: 38474338
[TBL] [Abstract] [Full Text] [Related]
14. The Transcriptional Landscape of Immune-Response 3'-UTR Alternative Polyadenylation in Melanoma.
Yang X; Wu Y; Chen X; Qiu J; Huang C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474285
[TBL] [Abstract] [Full Text] [Related]
15. Novel MED15::ATF1 fusion in a pediatric melanoma with spitzoid features and aggressive presentation.
Furtado LV; Cardenas M; Santiago T; Ruiz RE; Shi Z; Pappo A; Kacar M
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23230. PubMed ID: 38459940
[TBL] [Abstract] [Full Text] [Related]
16. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract] [Full Text] [Related]
17. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma.
Zhang X; Meng X; Wang P; Luan C; Wang H
Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263
[TBL] [Abstract] [Full Text] [Related]
18. The Role of the PTEN Tumor Suppressor Gene and Its Anti-Angiogenic Activity in Melanoma and Other cancers.
Maphutha J; Twilley D; Lall N
Molecules; 2024 Feb; 29(3):. PubMed ID: 38338464
[TBL] [Abstract] [Full Text] [Related]
19. CD133-Dependent Activation of Phosphoinositide 3-Kinase /akt/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.
Kharouf N; Flanagan TW; Alamodi AA; Al Hmada Y; Hassan SY; Shalaby H; Santourlidis S; Hassan SL; Haikel Y; Megahed M; Brodell RT; Hassan M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334632
[TBL] [Abstract] [Full Text] [Related]
20. GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
Booth MR; Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Feb; 15():124-133. PubMed ID: 38329728
[TBL] [Abstract] [Full Text] [Related]
[Next]
